-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On November 15, the CDE official website showed that Xinkanghe’s XKH001 injection clinical trial application was approved by the Food and Drug Administration for the treatment of moderate to severe asthma
XKH001 is the first IL-25 monoclonal antibody independently developed by Xinkanghe with global intellectual property rights
XKH001 can specifically neutralize human IL-25, block its binding to the receptor, and thereby inhibit the inflammatory response caused by Th2
It is worth noting that in July 2021, Xinkanghe announced that XKH001 was approved by the FDA for phase I clinical trials, becoming the world's first FDA-approved clinical IL-25 inhibitor